Comparison · NCT04726371-deaths
Generic Best Practices (GBP) vs Tailored Best Practices (TBP): deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Download JSON
Cite this record
ConductScience Library. Generic Best Practices (GBP) vs Tailored Best Practices (TBP): deaths from any cause. Trial comparisons, record NCT04726371-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04726371-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.000486 | 0.0000857 | 0.00275 | wilson | |
| Risk in group 2 | 0.000563 | 0.0000993 | 0.00318 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0000771 | -0.00273 | 0.00223 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.863 | 0.054 | 13.8 | log | |
| Odds ratio, group 1 over group 2 | 0.863 | 0.0539 | 13.8 | log | |
| Number needed to treat, for one fewer death from any cause on Generic Best Practices (GBP) than on Tailored Best Practices (TBP) | 13,000 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Generic Best Practices (GBP) | The 207 group homes randomized into this arm received the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consisted of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings.~Generic Best Practices: GBP consisted of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention received standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition did not represent inferior or substandard practice. As findings occurred and as policy led to adjustments in recommendations during the course of the study, the GBP condition incorporated recommendations that were appropriate and up-to-date with CDC and state policy. | 1 | 2,059 | EG000 |
| Group 2 | Tailored Best Practices (TBP) | The 208 group homes randomized into this arm received the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consisted of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm received coaching specific to the setting, staff, and residents.~Tailored Best Practices: TBP consisted of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. There were four main components to Tailored Best Practices: Measurement, Feedback, and House Plans; Motivational Interviewing; Interactive Education; and Trusted Messengers. | 1 | 1,777 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- Adverse event data were collected from baseline through 15-month follow-up, totaling 1 year and 6 months.
Source ClinicalTrials.gov
Trial
- Title
- Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings
- NCT number
- NCT04726371
- Phases
- NA
- Conditions
- Intellectual Disability, Developmental Disability, Axis I Diagnosis, Mental Illness, Covid19, Coronavirus
- Interventions
- Generic Best Practices, Tailored Best Practices
- Lead sponsor
- Massachusetts General Hospital
- Results first posted
- 2025-02-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04726371?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04726371-deaths